TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts ...

Presentations to cover progress across Eikon’s most advanced clinical-stage programsUpdated data will include those derived ...

An announcement from Eikon Therapeutics, Inc. ( (EIKN)) is now available. Eikon Therapeutics reported its first quarter 2026 results on May 11, 2026, highlighting a cash position of $596 million and a ...

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the ...

Robert Nevin, from Portrush, had no prior symptoms before his frightening experience two years ago. He woke in the middle of the night with what he thought was indigestion, got up early the next day ...

I have been attending Balmoral Show since I was a young person (which doesn’t seem all that long ago!) Many who read this column will also have similar life-long experiences. Over the years, my reason ...

Mara Lesemann has 33+ years of background in banking and foreign exchange. She was voted a top writer at Quora in 2018. Gordon Scott has been an active investor and technical analyst or 20+ years. He ...

A late-stage clinical biopharmaceutical company advancing a pipeline of potential therapies for patients with unmet medical needs across oncology and neurologic diseases. A late-stage clinical ...

A new AI tool discovered by UC San Diego improved prediction of how multiple cancers may respond to treatment ...